WeylChem to Produce Grignard Reagents on an Industrial Scale
News Sep 15, 2008
WeylChem has announced its intention to produce reagents on an industrial scale for major manufacturers of pharmaceuticals, agrochemicals and poly-functionalized products. A complete series of Grignard type reagents will be produced at the company’s Elgin, South Carolina facility.
The scale-up in Grignard reagent production is in response to an industry need for suppliers with the capability to deliver higher volumes than is currently available in the United States.
WeylChem offers the technical packages and production capacity to reliably supply manufacturers with starter reactions, like the Grignard reaction. Grignard chemistry is an important tool in the formation of carbon-carbon bonds and for the formation of carbon-phosphorus, carbon-tin, carbon-silicon, carbon-boron and other carbon-heteroatom bonds.
According to Alain Angelac, Sales and Marketing Project Manager, the move to supply the market with Grignards on an industrial scale is commensurate with changes taking place in the manufacturing programs of large multi-national manufacturers. “A number of our customers have asked us if we can supply them with Grignard reagents on a commercial scale as they reconfigure plants for new projects, or as they adopt chemistries and processes that make it uneconomical to produce the reagents in-house,” he said.
“Our customers know we have a long history of sound production and management practices – the kind needed to reliably deliver hazardous chemistry wherever it is needed, like Grignard reagents. And they know that we have the ability to make these reagents on a scale large enough to ensure reliable supplies in the long-term,” he said.
“With the start-up of commercial scale Grignard reagents production at Elgin, we have taken the first step in serving customers as both a supplier of custom synthesis and a producer of functional products,” he said.
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019